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1 
Abstract 
Adenosine di-phosphate elevates pulmonary arterial blood pressure 
more effectively, more consistently, and for longer periods than other high 
energy nucleotides that are endowed with similar hypertensive powers. No 
support could be found for the theory that aggregation of platelets and 
formation of wedge-thrombi are responsible for the ADP-induced rise of 
blood pressure. 
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Introduction 
Pulmonary blood pressure is not constant. Physiological fluctuations 
3 
accompany rest, exercise, and acute as well as chronic exposure to altitude. 
Because pulmonary artery pressure was known to be elevated at high altitudes, 
the effects of acute and chronic exposure to high altitudes have been 
extensively analyzed.-* 
The present study originated from observations by Grover, et al., that 
pulmonary artery pressure in human subjects and in cattle living at altitudes 
5 8 
of 7,000 - 10,000 feet above sea level was elevated. * Furthermore, the 
investigators found that prolonged exposure to altitude sensitized the pul- 
9 
monary arteries towards hypertensive agents. 
Since 1929, reports have appeared in the literature stating that the 
intravenous injection of the high energy adenosine nucleotides alter pulmo¬ 
nary artery pressure. However, precise information regarding the mode of 
action of high energy nucleotides was lacking. We therefore analyzed the 
pulmonary pressure effects of several high energy nucleotides. The experi¬ 
ment included measurements of pulmonary and aortic pressure in animals living 
at near-sea-level,* as well as on animals who had been adapted to simulated 
altitudes of 11,000 feet. Since Gaarder had demonstrated that ADP aggregates 
platelets in vitro, I postulated that the possible mechanism of the nucleo¬ 
tide induced rise in pulmonary artery pressure was due to platelet aggregates 
blocking part of the capillary outflow of the pulmonary bed. If a large 
number of platelets were sequestered in the pulmonary vessels, a significant 
*Lexington, Kentucky (955 feet above sea level) 
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reduction in the arterial platelet count could be expected. Therefore, 
serial arterial platelet counts were undertaken during the injection of two 
nucleotides adenosine diphosphate (ADP) and guanosine diphosphate (GDP). 
Both these compounds were known to elevate pulmonary artery pressure. 
Finally, the literature relating to chemistry, physiology, pharmacology, and 
toxicology of the compounds was surveyed. 
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Historical Remarks 
I. Nucleotides 
In 1847, Justus von Liebig discovered inosinic acid, a metabolic 
11 
precursor of purines. In 1871, Friedrich Miescher identified nucleic 
acid. He isolated the nuclear components of white blood cells, using as 
his source of material cells extracted from discarded surgical bandages. 
By digesting these pus cells with pepsin and hydrochloric acid and then shak¬ 
ing these cells with ether, he obtained a leucocyte nuclei concentrate he 
called "nuclein". Picard, a co-worker of Miescher, treated salmon sperm 
using the above method and identified the purine base guanine.^ In 1885, 
Alfred Kossel isolated adenine from acid hydrolysates of beef pancreas 
nucleic acid. In 1894, Kossel succeeded in purifying cytosine from calf 
thymus-nucleic acid.^ In 1900, Ascoli obtained uracil following the acid 
hydrolysis of yeast-nucleic acid.^ The isolation of muscle adenylic acid 
(AMP) was accomplished in 1927 by Embden and Zimmerman.^ Two years later, 
adenosine triphosphate was purified by Lohmann, a co-worker of Otto Meyerhof 
17,18 
and by Fiske and Subbarow. 
The metabolic, biochemical and biophysical effects of high energy 
nucleotides in vivo was studied by Lohmann, Meyerhoff, Szent Gyorgyi, A. F. 
19 20 21 22 
and H. E. Huxley, and Fritz Lipmann. * * * 
The following is a summary of those reactions about which knowledge 
is necessary for the understanding of the chemical nature of the compounds 
that were used in our experiments. When purine or pyrimidine bases are 
combined with sugar, nucleosides are formed. If the nucleoside reacts with 
phosphoric acid, a nucleotide is formed (a phosphorylated nucleoside is 
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called a nucleotide). Two types of nucleotides are contained in nucleic 
acids: those nucleic acids containing the sugar moiety D-ribose are called 
ribonucleic acids (RNA) and those containing 2-deoxy-ribofuranose are called 
deoxy ribonucleic acids (DNA). Tissue also contains nucleotides that are 
not combined in nucleic acids. Most important of these are the adenosine 
phosphates which act as an energy source for muscle contraction and as an 
activator of enzymes and of metabolic precursors. Thus, AMP is of impor¬ 
tance in activation of phosphorylase. Likewise, ADP and ATP play an essen¬ 
tial part in oxidative phosphorylation and thus represent a source of 
energy. Many reactions such as the incorporation of sulfate into ester 
linkages in compounds like sulfated mucopolysaccharides require the pre¬ 
liminary formation of active sulfate with ATP. 
The biological importance of other nucleotides used in this study 
are as follows. Inosine is a metabolic precursor of adenine and guanine. 
It can be synthetized from adenosine by deamination with nitric acid in 
vitro. A guanine derivative is required for the oxidation of ketoglutaric 
acid to succinate. This is involved in oxidative phosphorylation with 
transfer of phosphate to guanosine diphosphate to form guonasine triphos¬ 
phate which is a source of stored energy. Cytidine triphosphate (CTP) is the 
only nucleotide effective in the jin vitro mitochondrial system for the bio- 
24 
synthesis of lecithin. 
II. Platelets* 
Slood platelets were first identified in 1842 by Donne who 
*The term "Blut-plattchen" (tr. blood platelets) was introduced by 
Bizzozero in 1881. Osier in 1883 translated Bizzoaero's work and thus intro¬ 
duced the word "platelets" into the English medical terminology.^-* 
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26 
called them "globulins”, and believed they were derived from "lymph”. 
In 1874, Osier referred to "organisms" in the blood of rats and man which he 
initially thought were bacteria.^ However, his illustrations leave no 
doubt that these "organisms" were platelets. In addition, Osler^® observed 
that these particles formed granular aggregates in coagulating blood. Hayem, 
who corroborated Osier's findings, thought that the "organisms" were pre- 
cursors of red cells and therefore called them "hematoblasts". In 1906 
Wright correctly said that platelets were fragments of the cytoplasm of 
29 
giant cells of bone marrow. These cells were described as early as 1869 
30 by Bizzozero and named megakaryocytes by Howell in 1890. 
The first attempt to count platelets was made by Riess in 1872, who 
31 
associated changes in the platelet count with various diseases. In 1878, 
Hayem reported normal platelet counts on human subjects (317,000 to 200,000) 
26 
that do not differ significantly from those accepted today. In 1882, 
Hayem suggested that platelet thrombi might play an important role in the 
arrest of bleeding and that a decrease in numbers or absence of platelets 
26 
would cause a disruption of the hemostatic process. Duke (1912) found 
that a close correlation existed between the number of platelets in the blood 
32 
and bleeding time. 
In 1956, Born discovered that platelets which had been known to 
contain histamine, 5-hydroxytryptame, and adrenaline, also had large amounts 
of adenosine triphosphate (ATP) (up to 4.5 jumoles ATP/g in platelets of pigs, 
33 
and 1.9 jumoles/g (wet weight) in human platelets). Furthermore, he obser¬ 
ved that ATP rapidly disappeared during clotting and that after coagulation 
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O *7 
of whole blood, ATP could no longer be recovered from serum. 
In 1960, Hellem described a fraction in red blood cells which he 
called "Factor R" which was "acidic, dialysable and heat stable." Factor 
R increased the adhesiveness of platelets. This adhesiveness was measured 
by noting the increase in the number of platelets in platelet-rich plasma 
which adhere to a glass column before and after they were treated with 
"Factor R". Intravenous injection into rabbits of "Factor R" was followed 
by a short-lasting decrease of the platelet count. This phenomenon was felt 
35 to be due to platelets being sequestered in the lungs and in other organs. 
In 1961, Gaarder showed that'Factor R'was adenosine diphosphate (ADP). 
He tested other nucleotides for their effect on the adhesiveness of human 
platelets and found that only deoxyadenosine diphosphate was active.^ In 
the same year, Born noted that ADP aggregated platelets in vitro. 
Aggregation of platelets by ADP was found to be a highly specific 
process. Substances closely related to ADP such as adenosine monophosphate 
(AMP) , adenosine and 2 chloroadenosine acted as cer>mpetative inhibitors of 
37 
ADP induced platelet aggregation. 
In addition to the above effects, the concentration of platelets in 
blood was found to fluctuate markedly with several physiological stimuli. 
For example, intensive physical exercise between one and ten minutes duration 
38 39 
might double the number of platelets. * Recently, changes in the peripheral 
blood platelet concentration have been noted in animals subjected to rapidly 
40 
changing atmospheric pressure. 
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Review of Literature 
In 1929, Drury and Szent-Gyorgyi performed the first experiments in 
which the effects of nucleotides upon the pulmonary circulation were 
41 
documented. Since that time, reports concerning both the action and the 
mechanism of the nucleotide induced pulmonary artery pressure changes have 
varied widely. 
A. N. Drury and Szent Gyorgyi isolated an extract from heart muscle 
and identified it as adenylic acid (AMP). "When injected intravenously into 
the whole animal, it disturbed the cardiac rhythm in a constant and definite 
At 
manner." 1 In the isolated heart-lung preparation, AMP caused an increase 
in pulmonary artery pressure believed to be due to a left-to-right shunt 
caused by dilation of coronary vessels. In 1931, Bennet and Drury who per¬ 
fused isolated rabbit lungs with Ringer's solution noted that addition of 
2-4 mg of adenylic acid (AMP) led to a "slight increase in pulmonary artery 
42 
pressure." However, the extracts used in these studies was not pure. Being 
a muscle extract, it presumably contained significant amounts of adenosine 
diphosphate. In 1948, Emmelin and Feldberg observed that injection of 0.2 
to 0.4 mg adenosine triphosphate into the right auricle or into the jugular 
vein of cats produced "a tremendous swelling of the pulmonary artery and the 
whole right heart, ventricle and auricle." At the same time, pulmonary artery 
43 pressure rose from 20 to 80 mm Hg. In 1933, Gaddum and Holtz reported 
that small doses of adenosine di- and tri-phosphate caused dilation of the 
pulmonary vessels in cats, while a vaso-constrictive effect became evident 
after injection of larger amounts of the same compound. Injection of 0.005 

9 
mg of adenosine and adenosine-monophosphate raised pulmonary artery pressure, 
though not as much as corresponding amounts of adenosine diphosphate.^^ 
In 1961, Gordon studied the effect of i.v. injections of adenosine mono-, 
di-, and tri-phosphate on right ventricular pressure of rats. Thirty 
;ug/kg caused a very small rise of 1 or 2 mm Hg.^ 
Two reports of the effect of adenosine compounds upon human subjects 
were available. Neither of them, however, contained measurements of pulmonary 
artery pressure. Davies injected ATP intravenously and intra-arterially. 
Some of his subjects "experienced peculiar sensations in the chest, reported 
difficulty in breathing, and had to cough during the injections," while 
46 
others stated that breathing became "easier!" The other report was by 
Davey who noted that 5 mg of ADP produced palpitation, light-headedness, 
47 
tightness of the chest, and tachycardia. 
In experiments with cats, Stoner and Green found that intravenous 
injection of adenine compounds led to a rise in pulmonary artery pressure; 
that ADP and ATP were equally effective pressor substances and that AMP 
caused but 1/3 and ITP 1/10 the magnitude of the response of ATP. Adenosine, 
guanylic acid (GMP) and cytidylic acid (CMP) were found to be inactive. The 
observed increases in pulmonary artery pressure were interpreted as being 
due to vaso-constriction. 
The following is a summary of extracellular reactions to adenosine 
compounds so far demonstrated: 
1. Dilation of peripheral and splanchnic vessels (ATP, AMP) s'4-5* 
48,49,50) 
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2. Inhibition of respiratory center (ATP)(48) 
3. Rise in venous pressure (ATP)(48) 
4. Fall in arterial pressure (ATP, ADP, AMP)(48,51,52,53) 
5. Dilatation of coronary arteries (AMP) (48,51,54) 
6. Decreased heart rate (ATP) (48,51) 
7. Dilatation - vaso-constriction of renal vessels (ATP) (48) 
8. Contraction of uterus (ATP) (48,51) 
9. Contraction of bladder (ATP) (48) 
10. Dilatation of cerebral vasculature (55) 
11. Aggregation of platelets (ADP) (10) 
Although it is known that adenine nucleotides influence pulmonary 
arterial pressure, the results have been variable. Furthermore, the evidence 
contained in the literature failed to elucidate the effect on pulmonary 
artery pressure of other nucleotides» including those in the pyrimidine 
group. No conclusive proof was available concerning the mechanism by which 
those nucleotides, which were known to raise pulmonary artery pressure, exerted 
their influence. 
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Theoretical Considerations 
Two possible mechanisms of nucleotide-induced pulmonary hyper¬ 
tension were considered by the author. 
1) Increased blood flow through the lungs; 
2) Increased resistance to the flow of blood in the pulmonary vascular bed, 
I. Increased Flow 
The possibility that a left to right shunt caused pulmonary hyper¬ 
tension following injection of nucleotides was suggested as early as 1929 
39 
by Drury and Szent Gyorgyi. They observed that an injection of adenosine 
isolated from muscle caused a rise in pulmonary artery pressure to three 
times its pre-injection level. This effect was ascribed to dilation of the 
coronary vessels. However, it is likely that the muscle extract contained 
significant amounts of ADP which caused the pressure changes. Since flow 
in the pulmonary stream bed can be doubled with only slight increases in 
56 
pulmonary artery pressure, the shunting theory formulated by Drury and 
Szent Gyorgyi was not acceptable. 
II. Increased Resistance 
It seemed possible that the nucleotide induced effect upon the pul¬ 
monary artery pressure might be due to changes in tone of the pulmonary 
vasculature. The pulmonary vasculature reacts to a number of physiological 
and pharmacological stimuli which increase or decrease pulmonary artery 
pressure through vaso-constriction or vaso-dilation, respectively. Anoxia, 
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sympathetic nerve stimulation, 5-hydroxytryptamine, hypertonic solutions, 
bacterial toxins, histamine, epinephrine and levarterenal cause vaso¬ 
constriction. Aminophylline, papaverine, tolazoline, nitrates and acetyl¬ 
choline produce vaso-dilation.^^ 
Gaddum and Holtz reported a series of experiments on the effects of 
the adenosine compounds on the pulmonary vasculature of isolated dog and 
cat lungs perfused at a constant flow rate with heparinized blood. By 
measuring the changes in volume of the isolated lungs, the authors concluded 
that adenosine, AMP, and ADP in small doses (0.1 mg) caused vasodilation 
44 
and larger doses (0.25 mg) resulted in a "vasoconstrictive effect". 
43 48 
Emmelin and Feldberg (1948) and Stoner and Green (1951) concluded 
that ATP caused systemic hypotension and pulmonary hypertension. The systemic 
effect was thought to be secondary to pulmonary vaso-constriction. However, 
Gordon (1961) showed that the systemic depressor action of adenosine com¬ 
pounds in rats was independent of pulmonary vaso-constriction. Rats which 
responded to injection of AMP, ADP, and ATP with a marked decrease in 
systemic pressure showed no concomitant changes in pulmonary artery pressure. 
Gordon suggested that the decrease in systemic artery pressure was solely due 
to peripheral vaso-dilatation.^ 
The possibility that the observed increase in pulmonary vascular 
resistance was secondary to mechanical obstruction was based on the following 
data found in the literature. 
Born injected ADP i*.v. into cats, and found a brief but dramatic 
decrease in the number of blood platelets. Of the four cats into which 
Born infused ADP, the systemic blood pressure remained unchanged in two. In 
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the other two, there was a brief pressure drop, followed by prompt re¬ 
establishment of pre-infusion levels. AMP and adenosine in molar concentra¬ 
tions equal to those of ADP elicited no change in the platelet count, but 
did cause a decrease in the systemic blood pressure. Thus, in some of Born's 
experiments, ADP reduced the platelet count without affecting blood pressure; 
in others AMP reduced blood pressure without affecting the platelet count.^ 
The author concluded from this evidence that ADP affected the platelet count 
independent of changes in blood pressure. 
Regoli and Clark subsequently showed that prior infusion of adenosine 
into rabbits followed by injection of ADP prevented the drop in platelets 
cause by ADP. They also demonstrated that the systemic vaso-dilator effects 
of adenosine and of ADP were independent of the changes in the platelet 
60 
count of the blood. 
Davey (1964) investigated the effect of ADP on chromium 51-labeled 
platelets in human subjects. He noted that intravenous doses of 2.5 - 20 mg 
ADP caused a significant reduction in arterial platelet count concomitant 
with an increase in radioactivity over the spleen and liver. When ADP was 
infused into the brachial artery, marked vaso-dilation took place in the 
injected extremity, unaccompanied by changes in the platelet count in blood 
taken from the same arm's brachial vein. Davey concluded that the reduction 
of platelets following administration of ADP into the systemic circulation 
was due to transient concentration of platelets in the splanchnic and 
pulmonary capillaries.^ 
In 1964, Nordoy and Chandler autopsied the lungs of male albino rats 
twenty seconds after intravenous injection of ADP (25 mg/lGOgm of body insight). 
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Numerous platelet thrombi were found in pulmonary capillaries. In animals 
which had been given lesser doses of ADP, the number of thrombi seen was 
smaller. In animals given 1 mg ADP/100 gm and sacrificed sixty seconds 
later, no platelet thrombi were observed, while a "moderate” number of thrombi 
was seen in animals given 7 mg ADP/100 gm. Respiration was invariably affected. 
Following the administration of small doses of ADP, there was slowing of 
respiration, while high doses caused complete arrest of breathing lasting up 
to sixty seconds. As cause for this phenomenon, the author considered 
"sudden occlusion of pulmonary capillaries", since infusion of small-particulate 
61 
matter (Sephadex) also elicited respiratory arrest. Finally, from clinical 
experience it was known that pulmonary artery pressure rises chronically in 
5 62 patients suffering from multiple pulmonary emboli. * Considering the 
above data, it was hypothesized that nucleotide-induced pulmonary hyperten¬ 
sion might be caused by the occlusion of pulmonary vessels by platelet 
aggregates. Moreover, if sufficient platelets were trapped in the lung, a 
decrease in arterial platelet counts should be expected. 

15 
Design of Study 
Since chemically pure nucleotides had not been systematically 
evaluated nor pressor responses of the pulmonary arteries accurately measured, 
it was decided to conduct a series of experiments to elucidate the response 
of pulmonary arterial pressure to naturally occurring nucleotides. In plan¬ 
ning the study, consideration was given to the appropriate statistical 
pre-requisities. The injections of nucleotides were given in random order 
and the significance of the data obtained was analyzed by paired T tests 
with associated probabilities between corresponding pairs of data. 
After the pulmonary hypertensive effect of the high energy nucleotides 
1 2 had been observed, * arterial platelet counts were made following the in¬ 
jection of two nucleotides found to cause pulmonary hypertension. These 
nucleotides were ADP which clumps platelets jji vitro and GDP which does not. 
Blood for platelet counts was drawn during the measurements of the ADP-and 
GDP-induced pulmonary arterial pressure rise. A correlative evlauation of 
the two phenomena under scrutiny i.e. the change in pulmonary artery pressure 
and arterial platelet count could thus be done. The statistical design for 
the platelet study was essentially the same as that used for the analysis 
of the pressor responses. 
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Methodology 
The experiments were conducted with calves (one to four months of 
age), weighing from fifty to seventy kilograms.* ** No sedative or tranquil- 
izing drugs were given, since evidence was available showing marked alterations 
63 
of circulation and respiration were caused by these agents. The animals 
64 
were catheterized in the usual manner. 
After clipping and cleaning the left side of the neck, a 14 gauge 
needle was thrust into the external jugular vein and a 36 inch length of 
PE/90 Adams Co. Intramedic polyethylene, saline filled catheter was inserted 
The catheter was now attached via a 3-way stop cock to a Statham pressure 
transducer which was connected with a Sanborn 151 recorder. The location 
of the catheter tip was monitored with the aid of the pressure records. 
The catheter was advanced manually. Pressure tracings of right ventricle 
and pulmonary artery were recorded. The position of the catheter was 
checked throughout each experiment and care taken that it was situated 
immediately beyond the pulmonary valves before the bifurcation. Using the 
3-way stop cock, measured doses of high energy nucleotides were rapidly 
injected. The catheter was flushed with 3 cc of normal saline after each 
injection. The stop cock arrangement allowed the use of the same catheter 
for injections as well as for the recording of pressure. Recording of 
tracings thus had to be interrupted for not more than five seconds during 
injections. 
In several experiments intra-aortic pressure was also studied. 
Polyethylene tubing was introduced into the dorsal aorta which was 
punctured percutaneously in the eleventh left intercostal space with a 
No. 14 gauge needle. Pressure measurements were recorded at paper speeds 
of 1.00 mm/sec. Zero reference point in standing animals was a mid-chest 
position; in animals, lying on the side, a point half the width of the 
chest. 
*Calves were used for the following reasons: 
1) Calves have a conspicuously reactive pulmonary vascular bed,(65,66). 
2) Calves are not disturbed by the experiment, e.g. they continue to eat 
while being catherized. 
3) Calves are large animals so that the taking of numerous blood samples 
presents no problem. 
4) In calves the position of external jugular veins and aorta is such as to 
render percutaneous catheterization easy. 
5) There are no difficulties in keeping calves in cages. 
**Three calves were maintained in a low pressure chamber at a simulated 
altitude of 11,000 feet. The chamber was opened only for feeding (twice a day) 
and during the experiments. 
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The following nucleotides were supplied by P-L Biochemicals, Inc., 
Milwaukee, Wisconsin: the 5' tri-, di-, and mono-phosphate ribonucleotides 
of the inosine, guanosine, and adenine in the purine nucleotide series and 
cytidine and uridine of the pyrimidine nucleotides. 
In the experiments in which the nucleotide effect on pulmonary 
arterial pressure was studied, 100 /ug of each of the above named compounds 
weiE dissolved in 5 cc of saline. In the experiments in which platelet 
counts and pulmonary artery pressure were monitored, equal molar amounts 
(2 x 10 7 moles) of ADP and GDP were dissolved in 5 cc of saline.* In each 
instance the total amounts were injected as a bolus dose. Blood samples 
for the platelet counts were withdrawn from the aorta. All injections 
(Saline, ADP and GDP) were given into the pulmonary artery in random order. 
Samples for platelet counts were withdrawn in accordance with the following 
time schedule: one preinjection sample, one sample 30 seconds after the 
injection of the test substance, followed by further withdrawals 1.5, 2.5, 
3.5, 4.5, 10 and 15 minutes later. At that time, blood pressure levels had 
invariably returned to pre-experimental values. 
Five cc llVacutainersM containing 6 mg of EDTA were used to collect 
the blood. To prevent clumping of platelets in the polyethylene catheter, 
blood was allowed to flow at a slow rate. Whenever time intervals between 
withdrawals of up to five minutes following injections were called for, the 
polyethylene catheter was filled with heparin. Thirty seconds before collec¬ 
tion of such samples, heparin was allowed to run out whereupon blood was 
*2 x 10-7 Moles represents 100 micrograms of ADP and 105 micro¬ 
grams of GDP, both dosages causing significant increases in pulmonary artery 
pressure. 
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withdrawn at a slow, steady rate. 
Platelets were counted by the phase contrast method as described by 
67 
Brecher and Cronkite. The significance of the obtained data was 
analyzed according to the paired T test. (For formulas, see Appendix.) 
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Results 
Table 1 shows mean pulmonary artery pressures* and their standard 
deviations, pressure change after injection of nucleotides, P values, and 
duration of observed effects. 
The triphosphate and diphosphate compounds of the purine bases 
adenosine (ATP, ADP), guanosine (GTP, GDP), and inosine (ITP, IDP) and the 
diphosphate compound of the pyrimidine uridine (UDP) elicited statistically 
significant pulmonary pressure responses. With the exception of UDP, all 
pyrimidine compounds that were tested and all monophosphate purine derivatives 
failed to engender significant pressure changes. Except for the guanosine 
group, the diphosphate compounds produced consistently greater rises of 
pulmonary pressure than did their triphosphate counterparts. Of the pyrimidine 
nucleotides, only uridine diphosphate led to significant changes in pulmonary 
pressure. CTP, CDP, CMP, UTP, and UMP were nonreactive. (Fig. 1 and 2). 
Individual examples of the effects of the nucleotides are detailed in Fig. 3 
and 4. ADP was the most potent agent. Doses as small as 1.25 ug (0.23 x 
-8 10“ moles) produced rises in pulmonary pressure by margins of greater than 
5 mm Eg (Table 2). 
As mentioned earlier, in several experiments pulmonary artery and 
aortic pressures were recorded simultaneously (Fig. 5). Whenever pulmonary 
pressure rose following the injection of lOOmg of ADP, the systemic arterial 
*Pulmonary artery pressures are represented throughout this report 
as averages of systolic and diastolic pressures. Mean values in the accom¬ 
panying tables refer to arithmetic midpoints from individual experiments of 
the various series under analysis. 
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Table 1 
Effect of injection of 100 ug of high energy nucleotides on 
pulmonary arterial pressure of calves (means, S.D., and P values). 
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Figure 3 
Effect of 100 yUg of adenosine nucleotides on pulmonary arterial 
pressure (A?,IP - adenosine monophosphate, ADP - adenosine diphosphate, 
ATP - adenosine triphosphate).* 
*In fig. 3-7, 
are depicted. 
results of representative individual experiments 
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Figure 4 
The effect of 100 of a diphosphate purine nucleotide, 
adenosine diphosphate (ADP) and a diphosphate pyrimidine nucleo¬ 
tide, uridine diphosphate (UDP) on pulmonary artery pressure (AD? 
adenosine diphosphate, UDP - uridine diphosphate). 
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Table 2: 
Minimum doses of nucleotides that increase pulmonary arterial 
pressure 5 mm Hg or more. (For identification of nucleotides, cp. 
p. 20 ) 
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MINIMUM EFFECTIVE DOSE 
Nucleotide Calf £11 Calf £12 
Microgranis Moles Micrograir^s Moles 
ITP 50 8.4 x 10~8 50 8.4 x 10~8 
IDP 25 
-8 
5.1 x 10 25 5.1 x 10"8 
UTP 50 
-8 
8.5 x 10 100 17 x 10-8 
UDP 25 5 x 10"8 50 10 x 10“8 
GTP 25 4.1 x 10-8 25 4.1 x 10~S 
GDP 50 10 x 10~8 25 5 x 10“8 
ATP 25 4.1 x 10“8 10 1.6 x 10-8 
ADP 5 1 x 10"8 1.25 .23 x 10"S 
| 
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Figure 5 
Effect of 100 ug adenosine diphisphate (ADP) on pulmonary 
arterial (PA) and aortic (AO) pressures (Time intervals: 1 sec.) 
The vertical scale on the left shows aortic pressure, the 
scale next to it pulmonary arterial pressure. 
tA) 
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pressure decreased, reaching its lowest level when the pulmonary pressure 
response reached its maximum. Aortic pressure then rapidly returned to 
its starting level while pulmonary arterial pressure remained elevated for 
several more minutes. The injection, at sealevel, of the nucleotide com¬ 
pounds into three high altitude (11,000 ft.) acclimatized calves showed 
significantly greater increases in pulmonary artery pressure than those 
observed in the low altitude calves (Table 3, Fig. 6). 
Some of the altitude acclimatized calves developed prolonged pulmonary 
hypertension following injection of high energy nucleotides (Fig. 7). These 
findings are noteworthy since similar responses had previously been observed 
only in new born animals.0 Neither had it been known that altitude accli¬ 
matized calves several months of age are capable of pulmonary pressure re¬ 
sponses of the kind under discussion, nor that high energy phosphates can 
trigger them. Repeated doses of the same nucleotides applied later on the 
same day caused pressure responses of shorter duration. (Fig. 7) 
Since it was known that solutions of low pH induce vasoconstrictor 
responses in the pulmonary vasculature, the pH of all nucleotide solutions 
was measured. As can be seen from Table 4, there was no correlation between 
the pH of a nucleotide solution and the observed pulmonary pressure 
68 
responses. 
No significant changes in the number of platelets were noted at any 
time after the injection of saline, ADP, or GDP despite the changes in the 
pulmonary artery pressure (Fig. 8, Table 5 Appendix). The standard deviations 
of platelet counts from six calves were very great, extending from 14,800 to 
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184,300 (Table 6). This range was greater than that found by Brecher et 
al., but about the same as that reported by Born and Gaarder. In some 
animals, platelet counts dropped initially, concomitant with the beginning 
of rise in pulmonary artery pressure. However, no further parallelism be¬ 
tween the two parameters under analysis was noted. 
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Table 3: 
Effect of injection of 100 ug of high energy nucleotides on 
pulmonary arterial pressure of three calves which had lived since 
birth at a simulated altitude of 11,000 feet. Measurement taken 
at near sea-level altitude (in mm KG). 
Drug Mean Pre-Exp. 
Values 
Mean Values 
(Max.) After 
Injection 
Pressure 
Change After 
Injection 
Duration of 
. Pressure Rise 
(in minutes) 
TP (5) 47 103 56 3 
DP (3) 34 89 55 9 
rTP (5) 43 86 43 4 
rDP (1) 65 115 50 12 
Numbers in parentheses are the numbers of obser¬ 
vations. For comparison with corresponding pulmonary artery pres 
sures recorded from animals living at near sea level throughout 
see Table 1. 
I 
i 
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Figure 6: 
Response to AD? of pulmonary arterial pressure of a calf 
which had lived since birth at a simulated altitude of 11,000 
feet (straight lines) and of a calf which lived at near-sea- 
level (dotted lines). The abscissa represents doses of ADP. 
Measurements taken at near sea-level altitudes. 
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Fig.6. 
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Figure 7: 
Left side of diagram: Response of pulmonary artery pressure 
at near sea level altitude to 100 ug GDP in four months old calf 
which had lived since birth at a simulated altitude of 11,000 
f eet. 
Right side: Responses of pulmonary artery pressure to 200 ug 
GTP injected five minutes after pressure had returned to normal 
level follov/ing foregoing experiment. 
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Table 4: 
pH measurement of nucleotide solutions which were used in the 
experiments observing pulmonary pressor effects. There is no corre 
lation between pH of the nucleotide solution and pulmonary pressor 
activity of nucleotide solution. ( cp. table 1 & fig. 1,2.) 
Nucleotide pH 
ATP 6.5 
ADP 5.5 
AMP 5.6 
ITP 5.0 
IDP 5.7 
IMP 6.6 
GTP 5.6 
GDP 6.2 
GMP 6.5 
UTP 5.2 
UDP 5.9 
UMP 6.5 
CTP 5.2 
CDP 5.6 
CMP 6.6 
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Figure 8: 
Graphic account of Table 6 in appendix showing no statistical 
significant change in platelet count with 100 ug of ADP induced 
pulmonary hypertension. Identical results were obtained follow¬ 
ing the injection of 103 ug of GDP. 
Vertical bars on platelet curve (lower line) represents the 
standard deviation of the individual mean platelet counts. 
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Table 6 42 
Platelet counts of calves 
of saline into pulmonary artery. 
eight samples collected during a 
after infusion of 5 cc 
Means of platelet counts of 
fifteen minute period. 
ANIMAL NUMBER OF MEAN STANDARD 
COUNTS PLATELET COUNT DEVIATION 
713,100 48,100 
329,700 68,500 
563,100 68,500 
893,800 14,800 
937,500 21,100 
665,300 184,300 6 8 
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Discussion 
The results of this study showed that in high and low altitude 
acclimatized calves pulmonary hypertension of up to sixty-five minutes 
duration could be induced by high energy nucleotides. The most potent of the 
nucleotides tested was ADP. Since ADP was known to be a specific aggregator 
35 
of platelets, I considered the possibility that the nucleotide induced 
hypertension was caused by occlusion of the pulmonary vessels with platelet 
aggregates. However, no correlation was found between changes in arterial 
platelet counts and nucleotide induced pulmonary hypertension by ADP. More¬ 
over, GDP which does not aggregate platelets, also caused pulmonary hyper¬ 
tension. In addition, the time course of the nucleotide-induced pulmonary 
hypertension was not consistent with the hypothesis that the hypertension 
was secondary to platelet aggregation. Platelet aggregates caused by ADP 
69,70 
disperse within a minute in vivo but the pulmonary hypertension per¬ 
sisted for up to sixty-five minutes. The data therefore indicate that the 
nucleotide-induced pulmonary hypertension is unrelated to platelet aggregation. 
Thus, the evidence presented in this paper identifies nucleotides 
as humoral pressor substances which act specifically on the pulmonary 
artery pressure. This finding of course does not prove that pulmonary hyper¬ 
tension is caused by these compounds. However, such a possibility cannot be 
ruled out because ADP is generally present in erythrocytes, leucocytes, and 
the 
platelets in/circulation through the pulmonary vasculature. 
The regional selectivity of the arterial pressor effect of ADP, was 
clearly shown as it elevated pulmonary arterial pressure and at the same 
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time caused a decrease in the systemic blood pressure. 
How then does the pressor effect of nucleotides upon pulmonary 
artery pressure fit into the current hemodynamic concepts of blood pressure 
9 7 
regulation in the lungs? In two studies by Blount and Vogel , and Schepers 
on high altitude hypertension and pulmonary heart disease ("cor pulmonale"), 
the authors implied that a humoral transmitter substance may be important 
in the pathogenesis of increased pulmonary vascular resistance. Their in¬ 
vestigations are summarized in the following paragraphs. 
9 
Blount and Vogel found that pulmonary artery pressure increased 
in normal subjects exposed to a critical level of environmentally induced 
hypoxia. The critical atmospheric pressure level lay at 7,500 feet or 
slightly above the altitude at which many million people reside. The phy¬ 
siological status of subjects residing at 10,000 feet, e.g., in Leadville, 
Colorado, differed from that of persons living below 7,500 feet in that ad¬ 
aptive pulmonary hypertension, represented a common finding in the high 
altitude subjects. The adaptive pulmonary artery hypertension of the Leadville 
type was due to increased resistance in the pulmonary circulation, and not 
to increased pulmonary blood flow. The hypertension could be counteracted 
by breathing air containing 44 per cent oxygen and by vaso-dilators such 
as tolazoline. 
Blount and Vogel described a number of pathological pulmonary 
conditions associated with chronic exposure to altitudes above 10,000 feet. 
These included pulmonary artery hypertension, chronic mountain sickness and 
the dramatic and dangerous syndrome of high altitude induced acute pulmonary 
edema. The authors concluded, "A primary increase in alveolar membrane 

45 
permeability, induced by some metabolic product or transmitter substance, 
may be important. 
Cor Pulmonale is a clinical condition in which hypertrophy and/or 
failure of the right ventricle is secondary to increased pulmonary vascular 
resistence to blood flow. G. W. H. Schepers presented a comprehensive 
summary of the subject, and distinguished between "primary," "secondary," 
and miscellaneous" cardiac states caused by pulmonary hypertension. The 
hypertension was characterized by obstruction in the pulmonary stream bed, 
and was due either to mechanical interference, e.g. kinking of the artery, 
massive thrombosis, generalized atheromatosis, or to "functionally induced 
increases of resistance in the terminal or pre-terminal pulmonary stream bed."^ 
The results of the experiments described in this paper indicate 
that nucleotides, particularly ADP, represent intermediate metabolites whose 
pressor effect upon the pulmonary circulation deserves further study. 
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Summary 
1) The high energy nucleotides ATP, ADP, GTP, GDP, ITP, IDP, and 
UDP in doses of 100 ug caused pulmonary hypertension. 
2) With the exception of UDP, the presso-active compounds were 
purines. 
3) None of the pyrimidines other than UDP nor any of the mono¬ 
phosphates were presso-active. 
4) ADP was the most potent presso-active high energy nucleotide, 
3) Magnitude and duration of response of pulmonary artery pressure 
was greatest in calves that were acclimatized to simulated altitudes of 
about 11,000 feet. 
6) Presso-active nucleotides induce prolonged responses in altitude- 
acclimatized calves of up to four months of age. 
7) No correlation was found between changes in arterial platelet 
counts and nucleotide induced pulmonary hypertension. 

APPENDIX 
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The following represents the statistical method used to 
evaluate data obtained from the pressor and platelet effects of 
the high energy nucleotides. 

49 
PAIRED T-TESTS WITH MISSING DATA 
Purpose 
This program produces t-tests with associated probabilities 
between corresponding pail's of elements of two groups, i.e. variable 
no. 1 of Group 1 is tested against variable no 1 of Group 2, etc. 
Options provided are: 
1. t-tests with associated probabilities for uncorrelated data 
2. t-tests with associated probabilities for correlated data. 
3. missing data is permitted with correlated or uncorrelated data 
4. rearrangement of the variables on input is allowed 
In uncorrelated t-tests, a test is performed to determine the homo¬ 
geneity of the variances of the variables, and the appropriate 
standard error of differences and degrees of freedom are chosen 
accordingly. The program will handle up to 200 variables in each 
70 
group. 

METHOD: 
50 
The following formulas are used in computing 
Sum: EX. 
EX. 
Mean: 
Var iance: 
NjEXj2 - (EXj)2 
N j(N j - 1) 
= s-2 5 i 
Standard deviation: /S. = SD. 
i i 
Standard error: SD. 
4Tj - 1 
SD; 
Coefficient of variation 
mean. 
T - ratio: meanj - meanj 
standard error of difference 
Standard error of difference 
Correlated variables - 
/var. + var- -2r. . /var:var. 
• J ij 1 J 
Uncorrelated variables 
(Unequal variances) 
J 
va r var. 
J 
N. i N . J 
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Uncorrelated variables - 
(Equal variances) 
s2 (- 
P 
— + 
N. 
where S 
2 (Nj - DS j2 + (Nj - l)S' 
N; + N. - 2 
' J 
Degrees of Freedom: 
for correlated variables N - 1 
' j 
for uncorrelated variables 
(unequal variances) 
(S? / N.)2 
Nj + 1 
(S? / Nj)2 
N + 1 
j 
where S_! = d 
N. 
J 
for uncorrelated variables - 
(equal variances) 
N. + N. - 2 
' J 
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In an attempt to make the platelet counts more accurate, an 
effort was made to count platelets by the method described by Bull 
7¥ 
et al. This method separates red cells from platelets by sede- 
mentation of EDTA treated whole blood in small bore plastic tubes. 
During sedementation, the red cells, probably because of their sur¬ 
face charge, trap some plasma which is free of platelets. This 
leads to an excess of platelets in the supernatant pla.sma which is 
then later corrected for by knowing the hematocrit value. Once 
the plasma layer has formed, a 3 ul capillary pipet is filled from 
the plasma layer and diluted. This solution is counted with a 70 
micra-aperture attached to a model A Coulter counter. This method 
is said to have a coefficient of variation of only 3.8 per cent. 
Unfortunately, the above method could not be adopted to this experi 
ment since it soon became evident that the sedimentation rate of 
calf blood averaged less than 0.5 mm per hour and the plasma layer 
formed so slowly that by the time a sufficient ammount accumulated 
for counting purposes, the platelets had undergone degeneration and 
the machine counts showed fluctuations on a single sample of greate 
than 50 per cent. 
7S~ 
Finally, platelets were counted by the method of Ingram in 
which the platelet rich plasma is separated from the red and white 
blood cells by placing the blood sample to be counted above a layer 
of Dow Corning silicone with a specific gravity of 1.0580 in a 
microhematocrit tube. When this microhematocrit tube is centri¬ 
fuged, the red blood cells due to their greater specific gravity 
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move through the silicone layer, leaving behind a platelet rich 
plasma which following dilution is counted with a Coulter counter 
in a manner similar to that described above. Again, this method 
could not be utilized since it appears that the calf red and white 
blood cells have a density which is not sufficient to precipitate 
them through the silicone layer which has been found to be effective 
for separating dog and rat blood. Thus the counts with this method 
also fluctuated widely due to the red and which cell fragments 
which remained in the diluted sample used to count the platelets. 
However on discussion with Dr. Ingram, it appears that this method 
should be promising once the specific gravity of the silicone 
separating solution is so adjusted to allow the calf red and white 
cells to sediment through it during centrifugation, while the 
platelets are left in the supernate. 
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